Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.
复制标题
DOI:
10.1186/s12967-018-1387-9
复制
发表时间:
2018-01-29
影响因子:
7.4
通讯作者:
Goodyear CS
中科院分区:
文献类型:
--
作者:
Carini C;Hunter E;Scottish Early Rheumatoid Arthritis Inception cohort Investigators;Ramadass AS;Green J;Akoulitchev A;McInnes IB;Goodyear CS
There is a pressing need in rheumatoid arthritis (RA) to identify patients who will not respond to first-line disease-modifying anti-rheumatic drugs (DMARD). We explored whether differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from early RA patients before methotrexate (MTX) treatment could assist in identifying non-response to DMARD and, whether there is an association between such a signature and RA specific expression quantitative trait loci (eQTL). We looked for the presence of a CCS in blood from early RA patients commencing MTX using chromosome conformation capture by EpiSwitch™. Using blood samples from MTX responders, non-responders and healthy controls, a custom designed biomarker discovery array was refined to a 5-marker CCS that could discriminate between responders and non-responders to MTX. We cross-validated the predictive power of the CCS by generating 150 randomized groups of 59 early RA patients (30 responders and 29 non-responders) before MTX treatment. The CCS was validated using a blinded, independent cohort of 19 early RA patients (9 responders and 10 non-responders). Last, the loci of the CCS markers were mapped to RA-specific eQTL. We identified a 5-marker CCS that could identify, at baseline, responders and non-responders to MTX. The CCS consisted of binary chromosome conformations in the genomic regions of IFNAR1, IL-21R, IL-23, CXCL13 and IL-17A. When tested on a cohort of 59 RA patients, the CCS provided a negative predictive value of 90.0% for MTX response. When tested on a blinded independent validation cohort of 19 early RA patients, the signature demonstrated a true negative response rate of 86 and a 90% sensitivity for detection of non-responders to MTX. Only conformations in responders mapped to RA-specific eQTL. Here we demonstrate that detection of a CCS in blood in early RA is able to predict inadequate response to MTX with a high degree of accuracy. Our results provide a proof of principle that a priori stratification of response to MTX is possible, offering a mechanism to provide alternative treatments for non-responders to MTX earlier in the course of the disease. The online version of this article (10.1186/s12967-018-1387-9) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子:
5.5
作者:
Barrera, P;van der Maas, A;van Riel, PLCM
通讯作者:
van Riel, PLCM
DOI:
10.1126/science.1260793
发表时间:
2015-02-06
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Battle A;Khan Z;Wang SH;Mitrano A;Ford MJ;Pritchard JK;Gilad Y
通讯作者:
Gilad Y
影响因子:
30.8
作者:
Fairfax, Benjamin P.;Makino, Seiko;Radhakrishnan, Jayachandran;Plant, Katharine;Leslie, Stephen;Dilthey, Alexander;Ellis, Peter;Langford, Cordelia;Vannberg, Fredrik O.;Knight, Julian C.
通讯作者:
Knight, Julian C.
影响因子:
4
作者:
Christova, Rossitza;Jones, Tania;Sheer, Denise
通讯作者:
Sheer, Denise
影响因子:
7
作者:
Garge, Nikhil;Pan, Huaqin;Bunger, Maureen K.
通讯作者:
Bunger, Maureen K.